RxDoctor Payments Data

Gregory Lantz, DPM

Foot & Ankle Surgery · Waterloo, IANPI 1154310456

Payments from drug & device makers

What this record shows

Stryker accounts for 88.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $2,599 and has fallen 84.2% since, to $411 in 2025.

$9,064in general payments, 2019–2025

Across 131 payments — averaging $69.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$8K
  • Smith+Nephew$210
  • Biocomposites Inc$150
  • Organogenesis Inc.$145
  • Treace Medical Concepts, Inc.$129
  • Paragon 28, Inc.$79
  • plus $317 from 10 others

What the payments were for

  • Travel & lodging$4,03545%
  • Food & beverage$5,02955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,064 in reported general payments places this provider in the 75th percentile of 112 foot & ankle surgery providers in Iowa.

See all foot & ankle surgery providers in Iowa

Medicare billing

Part B allowed, 2024
$172,539
Medicare patients
504
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl49$441
SsdSilver Sulfadiazine69$394
Doxycycline Monohydrate31$377
Celecoxib20$316
Silver Sulfadiazine58$302
Cephalexin22$233
Meloxicam35$117
Nystatin11$105
Mupirocin15$102
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$100
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$99
Gabapentin13$88

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →